Will children with cancer benefit from the new European Paediatric Medicines Regulation?
Author:
- 1 June 2009
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 45 (9) , 1535-1546
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European ConsortiumEuropean Journal of Cancer, 2009
- Survival of European children and young adults with cancer diagnosed 1995–2002European Journal of Cancer, 2009
- Gene-Expression Signatures in Breast CancerNew England Journal of Medicine, 2009
- Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristicsThe Journal of Pathology, 2009
- Clinical trials for children with cancer in Europe – Still a long way from harmonisation: A report from SIOP EuropeEuropean Journal of Cancer, 2008
- Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological FeaturesPLOS ONE, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- The impact of the ‘Clinical Trials’ directive on the cost and conduct of non-commercial cancer trials in the UKEuropean Journal of Cancer, 2007